Please wait a minute...
文章检索
预防医学  2022, Vol. 34 Issue (11): 1167-1171,1177    DOI: 10.19485/j.cnki.issn2096-5087.2022.11.017
  疾病控制 本期目录 | 过刊浏览 | 高级检索 |
2018—2021年武义县疑似预防接种异常反应监测结果
王晓柳, 汤元妃
武义县疾病预防控制中心免疫规划科,浙江 武义 321200
Surveillance of suspected adverse events following immunization in Wuyi County from 2018 to 2021
WANG Xiaoliu, TANG Yuanfei
Department of Immunization Planning, Wuyi Center for Disease Control and Prevention, Wuyi, Zhejiang 321200, China
全文: PDF(826 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解2018—2021年浙江省武义县疑似预防接种异常反应(AEFI)发生情况,为疫苗接种安全性评价提供依据。方法 通过中国免疫规划信息管理系统AEFI信息管理系统和预防接种信息管理系统,收集2018—2021年武义县AEFI病例资料,采用描述性流行病学方法分析2018—2021年武义县AEFI报告发生率及AEFI病例特征。结果 2018—2021年武义县共接种常规疫苗870 007剂次,报告AEFI 482例,年均报告发生率为55.40/10万。免疫规划疫苗AEFI报告发生率为67.75/10万,高于非免疫规划疫苗的44.00/10万(χ2=20.334,P<0.001)。一般反应435例,报告发生率为50.00/10万,主要表现为高热、局部红肿和硬结;异常反应39例,报告发生率为4.48/10万,过敏性反应占87.18%;偶合症7例;心因性反应1例;无疫苗质量事故和接种事故报告。AEFI报告发生率前五位疫苗为13价肺炎球菌多糖结合疫苗(269.11/10万)、无细胞百白破灭活脊灰和b型流感嗜血杆菌(结合)联合疫苗(204.23/10万)、23价肺炎球菌多糖疫苗(175.85/10万)、无细胞百白破联合疫苗(128.39/10万)、麻腮风联合减毒活疫苗(124.36/10万)。口服、皮内注射、皮下注射、肌内注射AEFI报告发生率分别为10.89/10万、49.88/10万、56.07/10万和57.78/10万。AEFI病例以0~<2岁为主,333例占69.09%。主要发生在接种后<1 d,336例占69.71%。结论 2018—2021年武义县AEFI以一般反应为主,免疫规划疫苗AEFI报告发生率较非免疫规划疫苗要高,主要发生人群为2岁以下儿童。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
王晓柳
汤元妃
关键词 疑似预防接种异常反应预防接种监测    
AbstractObjective To investigate the occurrence of suspected adverse events following immunization (AEFI) in Wuyi County, Zheijang Province from 2018 to 2021, so as to provide insights into safety assessment of vaccination. Methods The AEFI data in Wuyi County from 2018 to 2021 were collected from the AEFI Information Management System and Immunization Information Management System of National Immunization Information Management System in China. The reported incidence of AEFI and epidemiological characteristics of cases with AEFI were analyzed in Wuyi County from 2018 to 2021 using a descriptive epidemiological method. Results A total of 870 007 vaccine doses had been administered in Wuyi County from 2018 to 2021, and a total of 482 AEFI were reported, with annual mean reported incidence of 55.40/105. The incidence of AEFI associated with vaccines included in the national immunization program was significantly higher than those not included in the national immunization program (67.75/105 vs. 44.00/105; χ2=20.334, P<0.001). There were 435 individuals with general reactions (50.00/105 incidence), with high fever, local redness and swelling and solid nodes; 39 cases with abnormal reactions (4.48/105 incidence), including 87.18% allergic reactions; 7 cases with coincident syndrome and one case with psychogenic reaction; however, no vaccine quality or vaccination events were reported. The five vaccines with the greatest incidence of AEFI included 13-valent pneumococcal polysaccharide conjugate vaccine (269.11/105), diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus and Haemophilus b conjugate vaccine (204.23/105), 23-valent pneumococcal polysaccharide vaccine (175.85/105), tetanus, diphtheria, acellular pertussis vaccine (128.39/105) and combined live vaccine for measles, mumps and rubella (124.36/105). The reported incidence rates of AEFI were 10.89/105, 49.88/105, 56.07/105 and 57.78/105 following oral, intradermal, subcutaneous and intramuscular administrations, respectively. In addition, AEFI were predominantly found to occur in patients at ages of 0 to <2 years (333 cases, 69.09%), and AEFI predominantly occurred <1 day following immunization (336 cases, 69.71%). Conclusions General reactions were predominant types of AEFI following vaccination in Wuyi County from 2018 to 2021, and the reported incidence of AEFI associated with vaccines included in the national immunization program was significantly higher than those not included in the national immunization program. AEFI mainly occurred among children under 2 years of age.
Key wordssuspected adverse event following immunization    immunization    surveillance
收稿日期: 2022-07-21      修回日期: 2022-09-25      出版日期: 2022-11-10
中图分类号:  R186  
作者简介: 王晓柳,本科,副主任医师,主要从事免疫规划工作
引用本文:   
王晓柳, 汤元妃. 2018—2021年武义县疑似预防接种异常反应监测结果[J]. 预防医学, 2022, 34(11): 1167-1171,1177.
WANG Xiaoliu, TANG Yuanfei. Surveillance of suspected adverse events following immunization in Wuyi County from 2018 to 2021. Preventive Medicine, 2022, 34(11): 1167-1171,1177.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2022.11.017      或      http://www.zjyfyxzz.com/CN/Y2022/V34/I11/1167
[1] 中华人民共和国卫生部办公厅,国家食品药品监督管理局办公室.全国疑似预防接种异常反应监测方案[J].中国疫苗和免疫,2011,17(1):72-81.
General Office of Ministry of Health,General Office of State Administration for Food and Drug.National guideline for surveillance of adverse events following immunization[J].Chin J Vaccine Immunization,2011,17(1):72-81.
[2] 汤元妃. 2012—2014年武义县疑似预防接种异常反应监测分析[J].中国农村卫生事业管理,2016,36(7):875-877.
TANG Y F.Surveillance and analysis of adverse events following immunization in Wuyi County from 2012 to 2014[J].Chin Rural Health Serv Adm,2016,36(7):875-877.
[3] 张丽娜,李克莉,杜雯,等.2019年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2021,27(4):438-445.
ZHANG L N,LI K L,DU W,et al.Surveillance of adverse events following immunization in China,2019[J].Chin J Vaccine Immunization,2021,27(4):438-445.
[4] 张丽娜,李克莉,李燕,等.2020年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2022,28(2):208-217.
ZHANG L N,LI K L,LI Y,et al.Surveillance of adverse events following immunization in China,2020[J].Chin J Vaccine Immunization,2022,28(2):208-217.
[5] 郑祎,王丹丹,王梅玉婷,等.2016—2020年嘉兴市南湖区疑似预防接种异常反应监测分析[J].预防医学情报杂志,2021,37(9):1256-1263,1268.
ZHENG Y,WANG D D,WANG M Y T,et al.Surveillance and analysis of suspected adverse reactions to vaccination in Nanhu District of Jiaxing City from 2016 to 2020[J].J Prev Med Inf,2021,37(9):1256-1263,1268.
[6] 吴晓虹,章光明.金华市2015—2016年疑似预防接种异常反应监测分析[J].上海预防医学,2017,29(9):707-711.
WU X H,ZHANG G M.Surveillance analysis on adverse events following immunization in Jinhua in 2015-2016[J].Shanghai J Prev Med,2017,29(9):707-711.
[7] 周绍英,马瑞.宁波市疑似预防接种异常反应监测结果分析[J].预防医学,2018,30(3):274-277.
ZHOU S Y,MA R.Analysis on surveillance results of adverse events following immunization in Ningbo City[J].Prev Med,2018,30(3):274-277.
[8] 吴瑛,李瑞平,高彩红.2010—2020年上海市奉贤区南桥镇疑似预防接种异常反应监测数据分析[J].职业与健康,2022,38(5):654-657.
WU Y,LI R P,GAO C H.Analysis on surveillance data of adverse event following immunization in Nanqiao Town of Fengxian District in Shanghai from 2010-2020.[J].Occup Health,2022,38(5):654-657.
[9] 严波,周倩意,郑晓晖,等.中国儿童家长疑似预防接种异常反应知晓率的Meta分析[J].预防医学,2021,33(3):250-254.
YAN B,ZHOU Q Y,ZHENG X H,et al.Awareness rate of adverse events following immunization among Chinese parents:a meta-analysis[J].Prev Med,2021,33(3):250-254.
[10] 杜哲群,胡洁,沈国初,等.嘉兴市8月龄儿童接种MMR、MR疫苗疑似预防接种异常反应监测结果[J].预防医学,2020,32(11):1086-1090.
DU Z Q,HU J,SHEN G C,et al.Adverse events following immunization of measles,mumps and rubella,or measles and rubella combined attenuated live vaccine among 8-month-old children in Jiaxing[J].Prev Med,2020,32(11):1086-1090.
[11] 王晓娟,赵雄,曹琰.联合疫苗的发展及相关问题探讨[J].中国药品标准,2022,23(1):46-50.
WANG X J,ZHAO X,CAO Y.Progress and related problems on combined vaccine[J].Drug Stand China,2022,23(1):46-50.
[12] VERITY C M,GREENWOOD R,GOLDING J.Long-term intellectual and behavioral outcomes of children with febrile convulsions[J].N Engl J Med,1998,338(24):1723-1728.
[13] JACOBSEN J S,ACKERSON K B,SY S L,et al.Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting[J].Vaccine,2009,27(34):4656-4661.
[1] 张超, 罗小福, 刘艳, 沈建勇, 徐秦儿, 韩利萍, 马力. 湖州市老年人接种流感灭活疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(8): 701-704.
[2] 马艳艳, 陈小劲, 赵月. 朝阳区3~6岁儿童体质健康调查[J]. 预防医学, 2023, 35(7): 615-619.
[3] 徐杰, 陈棕棕, 骆水娟, 李欢龙. 富阳区市售食品食源性致病菌监测结果[J]. 预防医学, 2023, 35(7): 624-627.
[4] 潘晓东, 韩见龙, 陈苘. 鸡肉中多种抗生素超高效液相-静电场轨道阱高分辨质谱检测方法[J]. 预防医学, 2023, 35(5): 456-459.
[5] 钱晓萍, 罗小福, 凌健. 湖州市疫苗接种相关的过敏性皮疹监测结果[J]. 预防医学, 2023, 35(4): 339-341.
[6] 赵冲, 施文文. 富阳区监测哨点医院急诊就诊伤害病例特征分析[J]. 预防医学, 2023, 35(2): 155-157,161.
[7] 王炸亚, 叶莉霞, 吴锋. 宁波市2018—2021年出生儿童肠道病毒71型疫苗接种情况分析[J]. 预防医学, 2023, 35(10): 895-898.
[8] 何飞, 马永法, 顾春艳, 潘铭, 陈万庚. 2005—2021年盐都区水痘流行特征[J]. 预防医学, 2023, 35(1): 61-64.
[9] 江伟, 刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 顾雯雯, 张小平. 2017—2021年杭州市HPV疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 71-73,77.
[10] 张超, 沈建勇, 罗小福, 徐秦儿, 韩利萍. 2015—2021年湖州市MMR疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 74-77.
[11] 刘迎男, 杨景元, 李慧, 杨虹, 杲柏呈, 高雅, 李向春, 曹猛. 2013—2021年内蒙古自治区五类重点人群丙型肝炎监测结果[J]. 预防医学, 2022, 34(9): 941-945.
[12] 龚震宇, 龚训良. 全球消除脊髓灰质炎进展[J]. 预防医学, 2022, 34(8): 861-862.
[13] 傅天颖, 吴昊澄, 鲁琴宝, 丁哲渊, 王心怡, 杨珂, 吴晨, 林君芬. 2021年浙江省法定传染病疫情分析[J]. 预防医学, 2022, 34(8): 842-847.
[14] 林君芬. 浙江省防范输入性猴痘疫情的对策建议[J]. 预防医学, 2022, 34(8): 757-759.
[15] . 系统性红斑狼疮患者疫苗接种专家共识[J]. 预防医学, 2022, 34(12): 1189-1193.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed